Início › Doenças Pulmonares Intersticiais › Texas
Ensaios clínicos de Doenças Pulmonares Intersticiais em Texas
19 estudos para Doenças Pulmonares Intersticiais estão buscando participantes em locais em Texas.
Cidades em Texas
Texto oficial do estudo (Inglês)
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
- Baylor College of Medicine, Houston
RecrutandoFase 3
Idades 40 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT07201922LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Stryde Research, Carrollton
- Baylor University Medical Center, Dallas
- Discovery Clinical Trials, San Antonio
- e mais 1
RecrutandoFase 2
Idades de 18 a 80 · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT05798923FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
- Baylor University Medical Center, Dallas
- Metroplex Pulmonary & Sleep Center, McKinney
- UT Health San Antonio, San Antonio
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07540988A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
- The University of Texas Health Science Center at Houston, Houston
- University of Texas Health Science Center at San Antonio, San Antonio
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT06806592A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Denison
- GSK Investigational Site, El Paso
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT05878717A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
- GSK Investigational Site, Houston
- GSK Investigational Site, Temple
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT06572384A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
- El Paso Pulmonary Association, El Paso
- Baylor College of Medicine, Houston
- Baylor Scott and White Health, Temple
RecrutandoFase 2
Idades 40 e acima · Todos os sexos · Atualizado em 4 de set. de 2026 · NCT06968845A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
- Clinical Research Site, Houston
RecrutandoFase 2
Idades de 18 a 85 · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT07333183Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- Baylor University Medical Center, Dallas
- Baylor College of Medicine, Houston
- Houston Methodist Hospital, Houston
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT06911632DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Baylor University Medical Center, Dallas
- UT Southwest Medical Center Heart and Lung Clinic, Dallas
- Houston Methodist, Houston
- e mais 1
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 26 de ago. de 2026 · NCT06388421Platform Clinical Study for Conquering Scleroderma
- University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT06195072PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
- University of Texas Southwestern, Dallas
RecrutandoEstudo observacional
Idades de 18 a 80 · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT06855329Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- University of Texas Southwestern, Dallas
- Baylor University Medical Center at Dallas, Dallas
- Baylor College of Medicine, Houston
- e mais 2
RecrutandoEstudo observacional
Idades 21 e acima · Todos os sexos · Atualizado em 12 de ago. de 2026 · NCT01915511A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
- Houston Methodist Hospital, Houston
RecrutandoFase 2
Idades de 18 a 80 · Todos os sexos · Atualizado em 10 de ago. de 2026 · NCT07175038Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- Baylor University Medical Center, Dallas
- UT Southwestern Medical Center-Advanced Lung Clinic, Dallas
- Houston Methodist Outpatient Center, Houston
- e mais 4
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 13 de jul. de 2026 · NCT05943535TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
- Baylor College of Medicine/Texas Children'S Hospital, Houston
RecrutandoEstudo observacional
Até 24 anos · Todos os sexos · Atualizado em 22 de jun. de 2026 · NCT04098445A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
- Galderma Investigational Site#7096, Arlington
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 31 de mar. de 2026 · NCT07047690Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
- University of Texas Southwestern Medical Center, Dallas
- Metroplex Pulmonary and Sleep Center, McKinney
- Research Centers of America, McKinney
RecrutandoFase 2
Idades 40 e acima · Todos os sexos · Atualizado em 12 de nov. de 2025 · NCT05975983Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Dallas
- aTyr Investigative Site, Houston
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 7 de mai. de 2025 · NCT05892614Fonte: ClinicalTrials.gov, dados obtidos em 1 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.